Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors

NCT05867251 is registered in ClinicalTrials.gov with Avenzo Therapeutics, Inc. as lead sponsor.

NCT NCT05867251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05867251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors
Lead sponsor
Avenzo Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 30, 2023
Completion date
January 31, 2030
Enrollment
430 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, ccne1 amplification, endometrial cancer, epithelial ovarian cancer, fallopian tube cancer, hr+, her2-, advanced breast cancer, hr+/her2- breast cancer, primary peritoneal cancer, tnbc - triple-negative breast cancer